Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

autologous UV-oHSV2-activated peripheral blood mononuclear cells

A preparation of autologous peripheral blood mononuclear cells (PBMCs) activated ex vivo by ultraviolet-inactivated oncolytic herpes simplex virus type 2 (UV-oHSV2), with potential immunomodulating and antineoplastic activities. Upon reintroduction of the autologous UV-oHSV2-activated PBMCs into the patient, the activated immune cells kill tumor cells. Ex vivo UV-oHSV2 treatment induces natural killer (NK) cell proliferation and the secretion of interferon-gamma (IFNg). This leads to immune-mediated tumor cell death and the inhibition of tumor cell proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous ultraviolet inactivated oncolytic herpes simplex virus type 2-activated peripheral blood mononuclear cells
autologous UV-oHSV2-activated PBMCs
autologous VAK immune cells
autologous virus-activated killer immune cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search